|Application ||WB, IHC|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||44461 Da|
|Homology||Rat - 12/13 amino acid residues identical; mouse - 11/13 amino acid residues identical.|
|Other Names||B2 bradykinin receptor, B2R, BK-2 receptor, BDKRB2, BKR2|
|Related products for control experiments||Control peptide antigen (supplied with the antibody free of charge).|
|Target/Specificity||Peptide GKRFRKKSWEVYQG(C), corresponding to amino acid residues 336-349 of human BKRB2 (Accession P30411). Intracellular, C-terminus.|
|Peptide Confirmation||Confirmed by amino acid analysis.|
|Application Details||Western blot analysis (WB): - Mouse spinal cord (see Dutra, R.C. et al. (2013) in Product Citations). Immunohistochemistry (IH): - Rat lung sections (see Duehrkop, C. et al. (2013) in Product Citations).|
|Format||Affinity purified antibody, lyophilized powder|
|Reconstitution||50 µl or 0.2 ml deionized water, depending on the sample size.|
|Antibody Concentration After Reconstitution||0.75 mg/ml.|
|Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Storage After Reconstitution||The reconstituted solution can be stored at 4ºC for up to 2 weeks. For longer periods, small aliquots should be stored at -20ºC or below. Avoid multiple freezing and thawing. The further dilutions should be made using a carrier protein such as BSA (1%). Centrifuge all antibody preparations before use (10000 × g 5 min).|
|Control Antigen Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Control Antigen Reconstitution||100 µl water.|
|Control Antigen Storage After Reconstitution||-20ºC.|
|Preadsorption Control||1 µg peptide per 1 µg antibody.|
|Formulation||Lyophilized powder. Reconstituted antibody contains phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kinins are small peptides produced rapidly following tissue injury that serve as important modulators of inflammation and pain. In the periphery, the actions of kinins include vasodilatation, increased vascular permeability, stimulation of immune cells, and induction of pain. Kinins in the central nervous system (CNS) seem to initiate a similar cascade of events leading to neural tissue damage, as well as long lasting disturbances affecting blood-brain barrier function.1 Kinins, such as Bradykinin (BK), Lys-BK, desArg9-BK, and Lys-desArg9-BK, exert their action via two distinct receptors: the B1 Bradykinin receptor (BKRB1) and the B2 Bradykinin receptor (BKRB2). BKRB2 is activated by BK and Lys-BK while desArg9-BK and Lys-desArg9-BK activate BKRB1.2 Activation of BKRB2 liberates mediators of vascular tone, fibrinolysis, and pain. BKRB2, which mediates most of the physiological effects of kinins, as well as BKRB1, represent potential therapeutic targets for treatment of inflammatory disorders and cardiovascular diseases. Both BKRB1 and BKRB2 are members of the seven-transmembrane domain, G protein-coupled receptor (GPCR) superfamily and share a common structure of seven putative transmembrane domains, an extracellular amino terminus, and a cytoplasmic carboxy terminus. BKRB2 is constitutively and widely expressed throughout the CNS and peripheral nervous system and on various cell types including endothelial cells, nerve fibers, leukocytes, and mast cells.3-5
1. Walker, K. et al (1995) Neurochem. Int. 26, 1.
2. Böckmann, S. and Paegelow, I. (2000) J. Leukoc. Biol. 68, 587
3. Hess, J.F. et al. (2004) J. Pharmacol. Exp. Ther. 310, 488.
4. Souza, D.G. et al. (2004) J. Immunol. 172, 2542
5. Calixto, J.B. et al. (2000) Pain 87, 1.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.